Ashkani, Emily G.
McKenna, Brian D.
Bryant, Jennifer L.
Trevisan-Silva, Dilza
Sherman, Nicholas E.
Chianese-Bullock, Kimberly A.
Slingluff, Craig L. Jr.
Funding for this research was provided by:
Celldex
Glaxo-Smith Kline
Merck
3M
Theraclion
Polynoma
Virginia Cancer Center Support Grant (P30 CA044579)
Article History
Accepted: 6 June 2024
First Online: 19 June 2024
Declarations
:
: Craig L. Slingluff, Jr. has the following disclosures: Research support to the University of Virginia from Celldex (funding, drug), Glaxo-Smith Kline (funding), Merck (funding, drug), 3 M (drug), Theraclion (device staff support); Funding to the University of Virginia from Polynoma for PI role on the MAVIS Clinical Trial; Funding to the University of Virginia for roles on the Scientific Advisory Board for CureVac. Also, Craig L. Slingluff, Jr. receives licensing fee payments through the UVA Licensing and Ventures Group for patents for peptides used in cancer vaccines.